Table 3.
Significant Human KEGG Pathway
| Seven Weeks |
| hsa04722 Neurotrophin signaling pathway |
| CAMK2G; calcium/calmodulin-dependent protein kinase II gamma |
| NTRK2; neurotrophic tyrosine kinase, receptor, type 2 |
| RAP1B; RAP1B, member of RAS oncogene family |
| SHC3; SHC (Src homology 2 domain containing) transforming protein 3 |
| hsa04510 Focal adhesion |
| PRKCB; protein kinase C, beta |
| RAP1B; RAP1B, member of RAS oncogene family |
| SHC3; SHC (Src homology 2 domain containing) transforming protein 3 |
| SPP1; secreted phosphoprotein 1 |
| hsa04012 ErbB signaling pathway |
| hsa05214 Glioma |
| CAMK2G; calcium/calmodulin-dependent protein kinase II gamma |
| PRKCB; protein kinase C, beta |
| SHC3; SHC (Src homology 2 domain containing) transforming protein 3 |
| hsa04062 Chemokine signaling pathway |
| PRKCB; protein kinase C, beta |
| RAP1B; RAP1B, member of RAS oncogene family |
| SHC3; SHC (Src homology 2 domain containing) transforming protein 3 |
| hsa05200 Pathways in cancer |
| PRKCB; protein kinase C, beta |
| RALA; v-ral simian leukemia viral oncogene homolog A (ras related) |
| TCEB1; transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) |
| hsa04010 MAPK signaling pathway |
| NTRK2; neurotrophic tyrosine kinase, receptor, type 2 |
| PRKCB; protein kinase C, beta |
| RAP1B; RAP1B, member of RAS oncogene family |
| hsa04720 Long-term potentiation |
| CAMK2G; calcium/calmodulin-dependent protein kinase II gamma |
| PRKCB; protein kinase C, beta |
| RAP1B; RAP1B, member of RAS oncogene family |
| hsa01100 Metabolic pathways |
| ATP6V1H; ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H |
| NDUFS4; NADH dehydrogenase (ubiquinone) Fe-S protein 4 |
| RDH11; retinol dehydrogenase 11 |
| Combined Analysis |
| hsa01100 Metabolic pathways |
| ACSL1; acyl-CoA synthetase long-chain family member 1 |
| ADC; arginine decarboxylase |
| NDUFS4; NADH dehydrogenase (ubiquinone) Fe-S protein 4 |
| RDH11; retinol dehydrogenase 11 |
The pathways were identified with the DE genes at seven weeks and regardless of age (7 and 16 weeks; combined analysis). Pathways having more than two genes are reported; no significant pathway was found at 16 weeks.